Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen

Journal of Autoimmunity

Volumn 39, Issue 4, 2012, Pages 304-314

  Hirose, Misa ^a   Vafia, Katerina ^a   Kalies, Kathrin ^a   Groth, Stephanie ^a   Westermann, Jürgen ^a   Zillikens, Detlef ^a   Ludwig, Ralf J ^a   Collin, Mattias ^b   Schmidt, Enno ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Autoantibody; Bullous; EndoS; Hydrolysis; IgG

Indexed keywords

AUTOANTIBODY; COLLAGEN TYPE 4; CYTOKINE; ENDOGLYCOSIDASE; FC RECEPTOR; GLYCAN; GLYCOSIDASE; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; DISEASE ACTIVITY; DISEASE COURSE; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYDROLYSIS; IMMUNIZATION; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; STREPTOCOCCUS PYOGENES;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; BACTERIAL PROTEINS; COLLAGEN TYPE VII; DISEASE MODELS, ANIMAL; GLYCOSIDE HYDROLASES; HUMANS; HYDROLYSIS; LEUKOCYTES; MICE; MICE, INBRED BALB C; PEMPHIGOID, BULLOUS; POLYSACCHARIDES; RABBITS; RECEPTORS, IGG; RECOMBINANT PROTEINS; SKIN; STREPTOCOCCUS PYOGENES;

EID: 84869878298     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.04.002     Document Type: Article

References (44)

1. Lim P.L., Zouali M. Pathogenic autoantibodies: emerging insights into tissue injury. Immunol Lett 2006, 103:17-26.
2. Nandakumar K.S., Holmdahl R. Therapeutic cleavage of IgG: new avenues for treating inflammation. Trends Immunol 2008, 29:173-178.
3. Stanley J.R., Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006, 355:1800-1810.
4. Schmidt E., Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010, 10:84-89.
5. Sticherling M., Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev 2011.
6. Woodley D.T., Briggaman R.A., O'Keefe E.J., Inman A.O., Queen L.L., Gammon W.R. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984, 310:1007-1013.
7. Woodley D.T., Burgeson R.E., Lunstrum G., Bruckner-Tuderman L., Reese M.J., Briggaman R.A. Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J Clin Invest 1988, 81:683-687.
8. Labib R.S., Anhalt G.J., Patel H.P., Mutasim D.F., Diaz L.A. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 1986, 136:1231-1235.
9. Giudice G.J., Emery D.J., Diaz L.A. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992, 99:243-250.
10. Chen M., Keene D.R., Costa F.K., Tahk S.H., Woodley D.T. The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis bullosa acquisita autoantibodies. J Biol Chem 2001, 276:21649-21655.
11. Sitaru C., Mihai S., Otto C., Chiriac M.T., Hausser I., Dotterweich B., et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005, 115:870-878.
12. Liu Z., Diaz L.A., Troy J.L., Taylor A.F., Emery D.J., Fairley J.A., et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993, 92:2480-2488.
13. Nishie W., Sawamura D., Goto M., Ito K., Shibaki A., McMillan J.R., et al. Humanization of autoantigen. Nat Med 2007, 13:378-383.
14. Recke A., Sitaru C., Vidarsson G., Evensen M., Chiriac M.T., Ludwig R.J., et al. Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of dermal-epidermal separation. J Autoimmun 2010, 34:435-444.
15. Sakai L.Y., Keene D.R., Morris N.P., Burgeson R.E. Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol 1986, 103:1577-1586.
16. Wetzels R.H., Robben H.C., Leigh I.M., Schaafsma H.E., Vooijs G.P., Ramaekers F.C. Distribution patterns of type VII collagen in normal and malignant human tissues. Am J Pathol 1991, 139:451-459.
17. Lapiere J.C., Woodley D.T., Parente M.G., Iwasaki T., Wynn K.C., Christiano A.M., et al. Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest 1993, 92:1831-1839.
18. Gammon W.R., Murrell D.F., Jenison M.W., Padilla K.M., Prisayanh P.S., Jones D.A., et al. Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. J Invest Dermatol 1993, 100:618-622.
19. Tanaka T., Furukawa F., Imamura S. Epitope mapping for epidermolysis bullosa acquisita autoantibody by molecularly cloned cDNA for type VII collagen. J Invest Dermatol 1994, 102:706-709.
20. Sitaru C., Kromminga A., Hashimoto T., Brocker E.B., Zillikens D. Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am J Pathol 2002, 161:301-311.
21. Woodley D.T., Chang C., Saadat P., Ram R., Liu Z., Chen M. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol 2005, 124:958-964.
22. Woodley D.T., Ram R., Doostan A., Bandyopadhyay P., Huang Y., Remington J., et al. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol 2006, 126:1323-1330.
23. Sitaru C., Chiriac M.T., Mihai S., Buning J., Gebert A., Ishiko A., et al. Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 2006, 177:3461-3468.
24. Mihai S., Chiriac M.T., Takahashi K., Thurman J.M., Holers V.M., Zillikens D., et al. The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol 2007, 178:6514-6521.
25. Chiriac M.T., Roesler J., Sindrilaru A., Scharffetter-Kochanek K., Zillikens D., Sitaru C. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J Pathol 2007, 212:56-65.
26. Shimanovich I., Mihai S., Oostingh G.J., Ilenchuk T.T., Brocker E.B., Opdenakker G., et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004, 204:519-527.
27. Sesarman A., Mihai S., Chiriac M.T., Olaru F., Sitaru A.G., Thurman J.M., et al. Binding of avian IgY to type VII collagen does not activate complement and leucocytes and fails to induce subepidermal blistering in mice. Br J Dermatol 2008, 158:463-471.
28. Allhorn M., Olin A.I., Nimmerjahn F., Collin M. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS One 2008, 3:e1413.
29. Nandakumar K.S., Collin M., Olsen A., Nimmerjahn F., Blom A.M., Ravetch J.V., et al. Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol 2007, 37:2973-2982.
30. Collin M., Olsen A. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J 2001, 20:3046-3055.
31. Collin M., Svensson M.D., Sjoholm A.G., Jensenius J.C., Sjobring U., Olsen A. EndoS and SpeB from Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis. Infect Immun 2002, 70:6646-6651.
32. Collin M., Shannon O., Bjorck L. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc Natl Acad Sci U S A 2008, 105:4265-4270.
33. Collin M., Olsen A. Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect Immun 2001, 69:7187-7189.
34. Albert H., Collin M., Dudziak D., Ravetch J.V., Nimmerjahn F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A 2008, 105:15005-15009.
35. Sitaru C., Schmidt E., Petermann S., Munteanu L.S., Brocker E.B., Zillikens D. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002, 118:664-671.
36. Kasperkiewicz M., Hirose M., Recke A., Schmidt E., Zillikens D., Ludwig R.J. Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita. Br J Dermatol 2010, 162:1064-1070.
37. Ludwig R.J., Recke A., Bieber K., Muller S., Marques Ade C., Banczyk D., et al. Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J Invest Dermatol 2011, 131:167-176.
38. Korman N.J. In situ-bound antibodies eluted from the skin of patients with bullous pemphigoid are preferentially directed against the 230-kD bullous pemphigoid antigen. J Invest Dermatol 1995, 105:824-830.
39. Allhorn M., Briceno J.G., Baudino L., Lood C., Olsson M.L., Izui S., et al. The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis. Blood 2010, 115:5080-5088.
40. van Timmeren M.M., van der Veen B.S., Stegeman C.A., Petersen A.H., Hellmark T., Collin M., et al. IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J Am Soc Nephrol 2010, 21:1103-1114.
41. Schreiber A., Xiao H., Jennette J.C., Schneider W., Luft F.C., Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009, 20:289-298.
42. Wijngaarden S., van de Winkel J.G., Jacobs K.M., Bijlsma J.W., Lafeber F.P., van Roon J.A. A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum 2004, 50:3878-3887.
43. Nimmerjahn F., Lux A., Albert H., Woigk M., Lehmann C., Dudziak D., et al. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A 2010, 107:19396-19401.
44. Kasperkiewicz M., Nimmerjahn F., Wende S., Hirose M., Iwata H., Jonkman M.F., et al. Genetic identification and functional validation of FcgammaRIV as key molecule in autoantibody-induced tissue injury. J Pathol 2012.